Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

NCT06297226 is registered in ClinicalTrials.gov with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor.

NCT NCT06297226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06297226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2024
Completion date
June 30, 2032
Enrollment
230 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma